Cardiac Troponin T and C-Reactive Protein for Predicting Prognosis, Coronary Atherosclerosis, and Cardiomyopathy in Patients Undergoing Long-term Hemodialysis

Christopher DeFilippi, Steven Wasserman, Salvatore Rosanio, Eric Tiblier, Heidi Sperger, Monica Tocchi, Robert Christenson, Barry Uretsky, Mathew Smiley, Judith Gold, Henry Muniz, John Badalamenti, Charles Herzog, William Henrich

Research output: Contribution to journalArticle

306 Citations (Scopus)

Abstract

Context: Cardiac troponin T (cTnT) and C-reactive protein (CRP) are prognostic markers in acute coronary syndromes. However, for patients with end-stage renal disease (ESRD) the ability of combinations of these markers to predict outcomes, and their association with cardiac pathology, are unclear. Objective: To investigate the association between levels of cTnT and CRP and long-term risk of cardiac pathology and death in patients with ESRD. Design, Setting, and Participants: A prospective cohort study initiated February through June 1998 and enrolling 224 patients with ESRD from 5 hemodialysis centers in the Houston-Galveston region of Texas. Levels of cTnT and CRP were analyzed at study entry in patients without ischemic symptoms. Main Outcome Measures: All-cause mortality during a mean follow-up of 827 (range, 29-1327) days. Secondary outcomes in predefined substudies were coronary artery disease (CAD), decreased (≤40%) left ventricular ejection fraction (LVEF), and presence of left ventricular hypertrophy (LVH). Results: One hundred seventeen (52%) patients died during follow-up. For levels of cTnT and CRP, progressively higher levels predicted increased risk of death compared with the lowest quartile (for cTnT quartile 2: unadjusted hazard ratio [HR], 2.2; 95% confidence interval [Cl], 1.2-4.1; quartile 3: HR, 2.7; 95% Cl, 1.5-4.9; quartile 4: HR, 3.0; 95% Cl, 1.6-5.3. For CRP quartile 2: HR, 0.9; 95% Cl, 0.5-1.6; quartile 3: HR, 1.8; 95% Cl, 1.1-3.1; quartile 4: HR, 1.8; 95% Cl, 1.1-3.2). Both cTnT and CRP remained independent predictors of death after adjusting for a number of potential confounders. The combination of cTnT and CRP results provided prognostic information when patients were divided into groups at or above and below the biomarker medians (high cTnT/high CRP levels vs low cTnT/low CRP levels for risk of death: HR, 2.5; 95% Cl, 1.5-4.0). Elevated levels of cTnT, but not CRP, were strongly associated with diffuse CAD (n = 67; 0%, 25%, 50%, and 62 % prevalence of multivessel CAD across progressive cTnT quartiles, P<.001). An LVEF of 40% or less was identified in 4 (9%), 3 (8%), 10 (27%), and 7 (19%) of patients across cTnT quartiles (P=.07). No trend for cTnT levels was found among patients with LVH (P=.45); similarly, no trend for CRP was found among patients with LVH (P=.65) or an LVEF of 40% or less (P=.75). Conclusions: Among stable patients with ESRD, increasing levels of cTnT and CRP are associated with increased risk of death. Furthermore, higher levels of cTnT may identify patients with severe angiographic coronary disease.

Original languageEnglish (US)
Pages (from-to)353-359
Number of pages7
JournalJournal of the American Medical Association
Volume290
Issue number3
DOIs
StatePublished - Jul 16 2003

Fingerprint

Troponin C
Troponin T
Cardiomyopathies
C-Reactive Protein
Renal Dialysis
Coronary Artery Disease
Chronic Kidney Failure
Left Ventricular Hypertrophy
Stroke Volume
Pathology
Acute Coronary Syndrome

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Cardiac Troponin T and C-Reactive Protein for Predicting Prognosis, Coronary Atherosclerosis, and Cardiomyopathy in Patients Undergoing Long-term Hemodialysis. / DeFilippi, Christopher; Wasserman, Steven; Rosanio, Salvatore; Tiblier, Eric; Sperger, Heidi; Tocchi, Monica; Christenson, Robert; Uretsky, Barry; Smiley, Mathew; Gold, Judith; Muniz, Henry; Badalamenti, John; Herzog, Charles; Henrich, William.

In: Journal of the American Medical Association, Vol. 290, No. 3, 16.07.2003, p. 353-359.

Research output: Contribution to journalArticle

DeFilippi, C, Wasserman, S, Rosanio, S, Tiblier, E, Sperger, H, Tocchi, M, Christenson, R, Uretsky, B, Smiley, M, Gold, J, Muniz, H, Badalamenti, J, Herzog, C & Henrich, W 2003, 'Cardiac Troponin T and C-Reactive Protein for Predicting Prognosis, Coronary Atherosclerosis, and Cardiomyopathy in Patients Undergoing Long-term Hemodialysis', Journal of the American Medical Association, vol. 290, no. 3, pp. 353-359. https://doi.org/10.1001/jama.290.3.353
DeFilippi, Christopher ; Wasserman, Steven ; Rosanio, Salvatore ; Tiblier, Eric ; Sperger, Heidi ; Tocchi, Monica ; Christenson, Robert ; Uretsky, Barry ; Smiley, Mathew ; Gold, Judith ; Muniz, Henry ; Badalamenti, John ; Herzog, Charles ; Henrich, William. / Cardiac Troponin T and C-Reactive Protein for Predicting Prognosis, Coronary Atherosclerosis, and Cardiomyopathy in Patients Undergoing Long-term Hemodialysis. In: Journal of the American Medical Association. 2003 ; Vol. 290, No. 3. pp. 353-359.
@article{0b74ce569e794497a7ec552d2bd861a6,
title = "Cardiac Troponin T and C-Reactive Protein for Predicting Prognosis, Coronary Atherosclerosis, and Cardiomyopathy in Patients Undergoing Long-term Hemodialysis",
abstract = "Context: Cardiac troponin T (cTnT) and C-reactive protein (CRP) are prognostic markers in acute coronary syndromes. However, for patients with end-stage renal disease (ESRD) the ability of combinations of these markers to predict outcomes, and their association with cardiac pathology, are unclear. Objective: To investigate the association between levels of cTnT and CRP and long-term risk of cardiac pathology and death in patients with ESRD. Design, Setting, and Participants: A prospective cohort study initiated February through June 1998 and enrolling 224 patients with ESRD from 5 hemodialysis centers in the Houston-Galveston region of Texas. Levels of cTnT and CRP were analyzed at study entry in patients without ischemic symptoms. Main Outcome Measures: All-cause mortality during a mean follow-up of 827 (range, 29-1327) days. Secondary outcomes in predefined substudies were coronary artery disease (CAD), decreased (≤40{\%}) left ventricular ejection fraction (LVEF), and presence of left ventricular hypertrophy (LVH). Results: One hundred seventeen (52{\%}) patients died during follow-up. For levels of cTnT and CRP, progressively higher levels predicted increased risk of death compared with the lowest quartile (for cTnT quartile 2: unadjusted hazard ratio [HR], 2.2; 95{\%} confidence interval [Cl], 1.2-4.1; quartile 3: HR, 2.7; 95{\%} Cl, 1.5-4.9; quartile 4: HR, 3.0; 95{\%} Cl, 1.6-5.3. For CRP quartile 2: HR, 0.9; 95{\%} Cl, 0.5-1.6; quartile 3: HR, 1.8; 95{\%} Cl, 1.1-3.1; quartile 4: HR, 1.8; 95{\%} Cl, 1.1-3.2). Both cTnT and CRP remained independent predictors of death after adjusting for a number of potential confounders. The combination of cTnT and CRP results provided prognostic information when patients were divided into groups at or above and below the biomarker medians (high cTnT/high CRP levels vs low cTnT/low CRP levels for risk of death: HR, 2.5; 95{\%} Cl, 1.5-4.0). Elevated levels of cTnT, but not CRP, were strongly associated with diffuse CAD (n = 67; 0{\%}, 25{\%}, 50{\%}, and 62 {\%} prevalence of multivessel CAD across progressive cTnT quartiles, P<.001). An LVEF of 40{\%} or less was identified in 4 (9{\%}), 3 (8{\%}), 10 (27{\%}), and 7 (19{\%}) of patients across cTnT quartiles (P=.07). No trend for cTnT levels was found among patients with LVH (P=.45); similarly, no trend for CRP was found among patients with LVH (P=.65) or an LVEF of 40{\%} or less (P=.75). Conclusions: Among stable patients with ESRD, increasing levels of cTnT and CRP are associated with increased risk of death. Furthermore, higher levels of cTnT may identify patients with severe angiographic coronary disease.",
author = "Christopher DeFilippi and Steven Wasserman and Salvatore Rosanio and Eric Tiblier and Heidi Sperger and Monica Tocchi and Robert Christenson and Barry Uretsky and Mathew Smiley and Judith Gold and Henry Muniz and John Badalamenti and Charles Herzog and William Henrich",
year = "2003",
month = "7",
day = "16",
doi = "10.1001/jama.290.3.353",
language = "English (US)",
volume = "290",
pages = "353--359",
journal = "JAMA - Journal of the American Medical Association",
issn = "0002-9955",
publisher = "American Medical Association",
number = "3",

}

TY - JOUR

T1 - Cardiac Troponin T and C-Reactive Protein for Predicting Prognosis, Coronary Atherosclerosis, and Cardiomyopathy in Patients Undergoing Long-term Hemodialysis

AU - DeFilippi, Christopher

AU - Wasserman, Steven

AU - Rosanio, Salvatore

AU - Tiblier, Eric

AU - Sperger, Heidi

AU - Tocchi, Monica

AU - Christenson, Robert

AU - Uretsky, Barry

AU - Smiley, Mathew

AU - Gold, Judith

AU - Muniz, Henry

AU - Badalamenti, John

AU - Herzog, Charles

AU - Henrich, William

PY - 2003/7/16

Y1 - 2003/7/16

N2 - Context: Cardiac troponin T (cTnT) and C-reactive protein (CRP) are prognostic markers in acute coronary syndromes. However, for patients with end-stage renal disease (ESRD) the ability of combinations of these markers to predict outcomes, and their association with cardiac pathology, are unclear. Objective: To investigate the association between levels of cTnT and CRP and long-term risk of cardiac pathology and death in patients with ESRD. Design, Setting, and Participants: A prospective cohort study initiated February through June 1998 and enrolling 224 patients with ESRD from 5 hemodialysis centers in the Houston-Galveston region of Texas. Levels of cTnT and CRP were analyzed at study entry in patients without ischemic symptoms. Main Outcome Measures: All-cause mortality during a mean follow-up of 827 (range, 29-1327) days. Secondary outcomes in predefined substudies were coronary artery disease (CAD), decreased (≤40%) left ventricular ejection fraction (LVEF), and presence of left ventricular hypertrophy (LVH). Results: One hundred seventeen (52%) patients died during follow-up. For levels of cTnT and CRP, progressively higher levels predicted increased risk of death compared with the lowest quartile (for cTnT quartile 2: unadjusted hazard ratio [HR], 2.2; 95% confidence interval [Cl], 1.2-4.1; quartile 3: HR, 2.7; 95% Cl, 1.5-4.9; quartile 4: HR, 3.0; 95% Cl, 1.6-5.3. For CRP quartile 2: HR, 0.9; 95% Cl, 0.5-1.6; quartile 3: HR, 1.8; 95% Cl, 1.1-3.1; quartile 4: HR, 1.8; 95% Cl, 1.1-3.2). Both cTnT and CRP remained independent predictors of death after adjusting for a number of potential confounders. The combination of cTnT and CRP results provided prognostic information when patients were divided into groups at or above and below the biomarker medians (high cTnT/high CRP levels vs low cTnT/low CRP levels for risk of death: HR, 2.5; 95% Cl, 1.5-4.0). Elevated levels of cTnT, but not CRP, were strongly associated with diffuse CAD (n = 67; 0%, 25%, 50%, and 62 % prevalence of multivessel CAD across progressive cTnT quartiles, P<.001). An LVEF of 40% or less was identified in 4 (9%), 3 (8%), 10 (27%), and 7 (19%) of patients across cTnT quartiles (P=.07). No trend for cTnT levels was found among patients with LVH (P=.45); similarly, no trend for CRP was found among patients with LVH (P=.65) or an LVEF of 40% or less (P=.75). Conclusions: Among stable patients with ESRD, increasing levels of cTnT and CRP are associated with increased risk of death. Furthermore, higher levels of cTnT may identify patients with severe angiographic coronary disease.

AB - Context: Cardiac troponin T (cTnT) and C-reactive protein (CRP) are prognostic markers in acute coronary syndromes. However, for patients with end-stage renal disease (ESRD) the ability of combinations of these markers to predict outcomes, and their association with cardiac pathology, are unclear. Objective: To investigate the association between levels of cTnT and CRP and long-term risk of cardiac pathology and death in patients with ESRD. Design, Setting, and Participants: A prospective cohort study initiated February through June 1998 and enrolling 224 patients with ESRD from 5 hemodialysis centers in the Houston-Galveston region of Texas. Levels of cTnT and CRP were analyzed at study entry in patients without ischemic symptoms. Main Outcome Measures: All-cause mortality during a mean follow-up of 827 (range, 29-1327) days. Secondary outcomes in predefined substudies were coronary artery disease (CAD), decreased (≤40%) left ventricular ejection fraction (LVEF), and presence of left ventricular hypertrophy (LVH). Results: One hundred seventeen (52%) patients died during follow-up. For levels of cTnT and CRP, progressively higher levels predicted increased risk of death compared with the lowest quartile (for cTnT quartile 2: unadjusted hazard ratio [HR], 2.2; 95% confidence interval [Cl], 1.2-4.1; quartile 3: HR, 2.7; 95% Cl, 1.5-4.9; quartile 4: HR, 3.0; 95% Cl, 1.6-5.3. For CRP quartile 2: HR, 0.9; 95% Cl, 0.5-1.6; quartile 3: HR, 1.8; 95% Cl, 1.1-3.1; quartile 4: HR, 1.8; 95% Cl, 1.1-3.2). Both cTnT and CRP remained independent predictors of death after adjusting for a number of potential confounders. The combination of cTnT and CRP results provided prognostic information when patients were divided into groups at or above and below the biomarker medians (high cTnT/high CRP levels vs low cTnT/low CRP levels for risk of death: HR, 2.5; 95% Cl, 1.5-4.0). Elevated levels of cTnT, but not CRP, were strongly associated with diffuse CAD (n = 67; 0%, 25%, 50%, and 62 % prevalence of multivessel CAD across progressive cTnT quartiles, P<.001). An LVEF of 40% or less was identified in 4 (9%), 3 (8%), 10 (27%), and 7 (19%) of patients across cTnT quartiles (P=.07). No trend for cTnT levels was found among patients with LVH (P=.45); similarly, no trend for CRP was found among patients with LVH (P=.65) or an LVEF of 40% or less (P=.75). Conclusions: Among stable patients with ESRD, increasing levels of cTnT and CRP are associated with increased risk of death. Furthermore, higher levels of cTnT may identify patients with severe angiographic coronary disease.

UR - http://www.scopus.com/inward/record.url?scp=0038263154&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038263154&partnerID=8YFLogxK

U2 - 10.1001/jama.290.3.353

DO - 10.1001/jama.290.3.353

M3 - Article

VL - 290

SP - 353

EP - 359

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0002-9955

IS - 3

ER -